Compare BKV & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKV | SUPN |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 452 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | N/A | 2010 |
| Metric | BKV | SUPN |
|---|---|---|
| Price | $25.94 | $46.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $34.22 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 820.0K | 713.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $69.39 | $22.70 |
| Revenue Next Year | $9.45 | $19.14 |
| P/E Ratio | $57.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.56 | $31.37 |
| 52 Week High | $32.81 | $59.68 |
| Indicator | BKV | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 52.65 |
| Support Level | $25.34 | $43.43 |
| Resistance Level | $30.17 | $46.79 |
| Average True Range (ATR) | 1.02 | 1.35 |
| MACD | 0.22 | 0.32 |
| Stochastic Oscillator | 81.94 | 89.83 |
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.